Hemostatic agent for jaw central hemangioma hemorrhage and a preparation method and application thereof

Patent metadata

Field	Value
Publication number	US-12491285-B2
Application number	US-202118008440-A
Country	US
Kind code	B2
Filing date	Jan 7, 2021
Priority date	Feb 11, 2020
Publication date	Dec 9, 2025
Grant date	Dec 9, 2025

Abstract

The invention relates to the field of biomedical engineering, and discloses a hemostatic agent for jaw central hemangioma hemorrhage and a preparation method and application thereof. The invention is as follows: chitosan powder and organic weak acid are added into organic alcohol to react, so as to prepare chitosan weak acid salt, and then the chitosan weak acid salt is mixed with carboxymethyl chitosan in proportion to obtain the hemostatic agent of the invention. The hemostatic agent of the invention has good fluidity and plasticity. When applied to the hemostasis of jaw central hemangioma hemorrhage, the hemostatic agent of the invention can quickly reach the point of jaw central hemangioma hemorrhage without any stimulation and damage to the tissue. In addition, the hemostatic agent of the invention can inhibit the growth of bacteria, eliminate cross infection, and is easy to clean and remove. Therefore, the hemostatic agent of the invention can safely and effectively treat the massive hemorrhage of jaw central hemangioma, which is worthy of clinical promotion. At the same time, the hemostatic agent of the invention can also be used for hemostasis of hemorrhage points in tissue cavities with special structures.

First claim

The invention claimed is:

1 . A preparation method for hemostatic agent for jaw central hemangioma hemorrhage, characterized comprising the following steps:
1) Adding chitosan powder and organic weak acid into organic alcohol, reacting at a temperature of 40 to 50° C. for 3 to 5 h, filtering the filtrate, washing with organic alcohol, and drying at a temperature of 40 to 50° C. so as to obtain chitosan weak acid salt, wherein the organic alcohol is one or two of ethanol and isopropanol, the organic weak acid is one or two of citric acid and lactic acid, wherein a usage of the organic alcohol: the chitosan powder: the organic weak acid is 100 ml:(10 to 20) g:(5 to 12) g; 2) Evenly mixing the chitosan weak acid salt and carboxymethyl chitosan to obtain a hemostatic agent, the content of carboxymethyl chitosan in the hemostatic agent is 8 to 17 wt %.

2 . The preparation method according to claim 1 , characterized in that the proportion of deacetylation of the chitosan powder is 75 to 99%, the molecular weight is 10 to 500 KDa, and the viscosity is 30 to 100 cP.

3 . The hemostatic agent prepared according to the preparation method of any one of claim 1 .

4 . The application of the hemostatic agent of claim 3 in the hemostasis of jaw central hemangioma hemorrhage.

Assignees

• Univ Nantong

Inventors

• Yang Yumin
• Zhu Jiang
• Wang Yongjun
• Zhang Luzhong
• Li Guicai
• Zhao Yahong
• Ling Jue
• Yang Pengxiang

Classifications

• A61L2400/04

  Materials for stopping bleeding · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61L24/08 Primary

  Polysaccharides {(A61L24/043 takes precedence)} · CPC title

• A61K31/722 Primary

  Chitin, chitosan · CPC title